Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
    1.
    发明授权
    Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV 失效
    核酸载体包含启动子和编码来自内源性逆转录病毒PCAV的多肽的序列

    公开(公告)号:US08518694B2

    公开(公告)日:2013-08-27

    申请号:US10587032

    申请日:2003-06-13

    IPC分类号: A61K48/00 C12N15/00

    摘要: A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2).

    摘要翻译: 一种核酸载体,其包含:(i)启动子; (ii)编码与所述启动子可操作地连接的HML-2多肽的序列; 和(iii)可选标记。 优选的载体包括:(I)真核启动子; (ii)编码在所述启动子下游并可操作地连接的HML-2多肽的序列,(iii)原核选择标记; (iv)原核复制起点; 和(v)在编码HML-2多肽的所述序列的下游并可操作地连接真核转录终止子。 本发明的载体在体外(例如用于后续纯化)中特别可用于表达HML-2多肽。 或体内(例如用于核酸免疫)。 它们非常适合于针对前列腺肿瘤的核酸免疫。 优选的HML-2是PCAV,其位于染色体22上,为20.428兆比特(22q11.2)。

    Vectors for expression of hml-2 polypeptides
    5.
    发明申请
    Vectors for expression of hml-2 polypeptides 失效
    用于表达hml-2多肽的载体

    公开(公告)号:US20100086565A1

    公开(公告)日:2010-04-08

    申请号:US10587032

    申请日:2003-06-13

    摘要: A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2).

    摘要翻译: 一种核酸载体,其包含:(i)启动子; (ii)编码与所述启动子可操作地连接的HML-2多肽的序列; 和(iii)可选标记。 优选的载体包括:(I)真核启动子; (ii)编码在所述启动子下游并可操作地连接的HML-2多肽的序列,(iii)原核选择标记; (iv)原核复制起点; 和(v)在编码HML-2多肽的所述序列的下游并可操作地连接真核转录终止子。 本发明的载体在体外(例如用于后续纯化)中特别可用于表达HML-2多肽。 或体内(例如用于核酸免疫)。 它们非常适合于针对前列腺肿瘤的核酸免疫。 优选的HML-2是PCAV,其位于染色体22上,为20.428兆比特(22q11.2)。